Severe Acute Respiratory Syndrome clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • Imaging Immune Activation in COVID-19

    open to eligible people ages 18 years and up

    This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.

    at UCSF

  • KIDney Injury in Times of COVID-19 (KIDCOV)

    open to eligible people ages 18 years and up

    There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.

    at UCSF

Our lead scientists for Severe Acute Respiratory Syndrome research studies include .

Last updated: